Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis-Reference-Cited by-同舟云学术

Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis

Published:2021-05-29 Issue:8 Volume:96 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Khurana Arushi¹^ORCID,Dalland Joanna C.²,Young Jason R.³,Inwards David J.¹^ORCID,Paludo Jonas¹^ORCID

Affiliation:

1. Division of Hematology Mayo Clinic Rochester Minnesota USA

2. Department of Laboratory Medicine and Pathology, Division of Hematopathology Mayo Clinic Rochester Minnesota USA

3. Department of Radiology, Division of Nuclear Medicine Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26233

Reference12 articles.

1. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma FDA.https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma. Accessed April 5 2021.

2. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

3. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

4. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

5. WangML RossiJM MunozJ et al. Pharmacological Profile and Clinical Outcomes of KTE‐X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA‐2 Trial.https://tct.confex.com/tct/2021/meetingapp.cgi/Paper/17221. Accessed April 5 2021.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas;Frontiers in Oncology;2024-07-01

2. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement;Leukemia & Lymphoma;2024-01-22

3. Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience;Cancers;2023-08-25

4. Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy;Frontiers in Bioengineering and Biotechnology;2023-06-14

5. Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research;Cancers;2023-01-30